At Rize Oncology, we are developing STS-201 for the treatment of soft tissue sarcoma.
STS-201 is a small molecule drug candidate that has exhibited significant utility in soft tissue sarcoma, as well as other types of cancers and certain proliferative diseases. The unique mechanism of action of STS-201 results in:
- A blockade of cell division at the late G2/M boundary, a site in the cell cycle that is believed to be optimal for radiation-induced damage.
- A slowing of the rate of tumor proliferation, which enables normalization of the tumor neo-vasculature. The result is better oxygenation and more efficient drug delivery.
- Increased oxygen in the tumor micro-environment, which increases sensitivity to radiation due to radiation-induced formation of reactive oxygen species.
- Formation of a more complete tumor vasculature, which reduces the poorly formed, disorganized vascular sites where metastatic cells penetrate the circulatory system.
Company Details
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.rizeoncology.com
- Keywords
- Lawrence.
Rize Oncology Questions
Rize Oncology's website is http://www.rizeoncology.com
Rize Oncology's LinkedIn profile is https://www.linkedin.com/company/rize-oncology
Rize Oncology's industry is
Biotechnology Research
Rize Oncology's top competitors are
Bioscience Oncology,
Eos Oncology, Inc.,
Muwells, Inc.,
Genetether Therapeutics Inc (Cse: Gttx),
Vivia Oncology,
Cession Oncology,
Fp&a Navigator,
Isoform Oncology,
Shackelford Pharma Inc,
Pinnacle Oncology.
Rize Oncology's categories are Biotechnology Research
